Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manoranjenni Chetty

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Current Drug Metabolism|March 29, 2012
Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensusManoranjenni Chetty, Donald Mattison, Amin Rostami-Hodjegan
European Journal of Clinical Pharmacology|May 8, 2020
Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?Manoranjenni Chetty, Michael P Danckwerts, Andrea Julsing
European Journal of Clinical Pharmacology|January 7, 2014
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenzPanjasaram Naidoo, Vasudevan V Chetty, Manoranjenni Chetty
Therapeutic Drug Monitoring|October 14, 2006
Therapeutic monitoring of clozapine in Australia: the need for consensusThein Z Oo, John F Wilson, Divania Naidoo, et al.
Clinical Pharmacokinetics|January 29, 2016
Potential Sources of Inter-Subject Variability in Monoclonal Antibody PharmacokineticsKatherine L Gill, Krishna K Machavaram, Rachel H Rose, et al.
Frontiers in Pharmacology|April 12, 2018
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of EfavirenzManoranjenni Chetty, Theresa Cain, Janak Wedagedera, et al.
Clinical and Translational Science|September 30, 2022
Design and conduct considerations for studies in patients with hepatic impairmentPaulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, et al.
Clinical Pharmacokinetics|January 10, 2013
Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodiesMiroslav Dostalek, Iain Gardner, Brian M Gurbaxani, et al.
Advanced Drug Delivery Reviews|September 7, 2018
Physiologically based pharmacokinetic modelling to guide drug delivery in older peopleManoranjenni Chetty, Trevor N Johnson, Sebastian Polak, et al.
Frontiers in Immunology|January 21, 2015
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn ModelManoranjenni Chetty, Linzhong Li, Rachel Rose, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Current Drug Metabolism|March 29, 2012
Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensusManoranjenni Chetty, Donald Mattison, Amin Rostami-Hodjegan
European Journal of Clinical Pharmacology|May 8, 2020
Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?Manoranjenni Chetty, Michael P Danckwerts, Andrea Julsing
European Journal of Clinical Pharmacology|January 7, 2014
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenzPanjasaram Naidoo, Vasudevan V Chetty, Manoranjenni Chetty
Therapeutic Drug Monitoring|October 14, 2006
Therapeutic monitoring of clozapine in Australia: the need for consensusThein Z Oo, John F Wilson, Divania Naidoo, et al.
Clinical Pharmacokinetics|January 29, 2016
Potential Sources of Inter-Subject Variability in Monoclonal Antibody PharmacokineticsKatherine L Gill, Krishna K Machavaram, Rachel H Rose, et al.
Frontiers in Pharmacology|April 12, 2018
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of EfavirenzManoranjenni Chetty, Theresa Cain, Janak Wedagedera, et al.
Clinical and Translational Science|September 30, 2022
Design and conduct considerations for studies in patients with hepatic impairmentPaulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, et al.
Clinical Pharmacokinetics|January 10, 2013
Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodiesMiroslav Dostalek, Iain Gardner, Brian M Gurbaxani, et al.
Advanced Drug Delivery Reviews|September 7, 2018
Physiologically based pharmacokinetic modelling to guide drug delivery in older peopleManoranjenni Chetty, Trevor N Johnson, Sebastian Polak, et al.
Frontiers in Immunology|January 21, 2015
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn ModelManoranjenni Chetty, Linzhong Li, Rachel Rose, et al.
Pageof 3